US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Trust NYSE Arca Biotechnology Index Fund

264.97

-5.9600-2.20%

Pre-market: 264.970.00000.00%04:00 EDT

Volume:71.47K

Turnover:18.95M

Market Cap:2.90B

PE:31.01

High:273.10

Open:273.10

Low:262.30

Close:270.93

52wk High:275.23

52wk Low:182.08

Shares:10.95M

Float Shares:10.95M

Volume Ratio:1.06

T/O Rate:0.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):8.55

EPS(LYR):37.75

ROE:19.96%

ROA:-0.16%

PB:1.04

PE(LYR):7.02

Loading ...

Overview Company News Filings

Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares

Alkermes Appoints Anne Whitaker to Board of Directors

Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors

THOMSON REUTERS

Brookfield Strikes $2.9 Billion Cash Deal for Australian Plumbing Supplier Reliance Worldwide

Fourth Bid Succeeds: Brookfield Clinches $2.9 Billion Deal for Australian Pipe Maker RWC at 32% Premium

Veracyte Adds Another Stream to Bladder Franchise, UBS Says

MT Newswires Live

Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer

Veracyte Completes Convergent Genomics Acquisition to Expand Urology

Veracyte Buys Convergent Genomics

MT Newswires Live

Veracyte acquires Convergent Genomics for $150M in cash upfront

Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform

THOMSON REUTERS

Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments

THOMSON REUTERS

Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028

THOMSON REUTERS

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Bruker Leadership Presents at Upcoming Wells Fargo Healthcare Conference

Video: Novartis slides after second recent drug development setback

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy

Mizuho survey shows no consensus into Alkermes ADHD data

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigeractivity.com/stock/FBT/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"FBT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","market":"US","secType":"STK","nameCN":"First Trust NYSE Arca Biotechnology Index Fund","latestPrice":264.97,"timestamp":1791316800000,"preClose":270.93,"halted":0,"volume":71469,"hourTrading":{"tag":"盘前","latestPrice":264.97,"preClose":264.97,"latestTime":"04:00 EDT","volume":1,"amount":264.97,"timestamp":1791360025951,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021998302144465284,"floatShares":10950002,"shares":10950002,"eps":8.545272,"marketStatus":"Pre-Mkt","change":-5.96,"latestTime":"10-07 06:57:00 EDT","open":273.1,"high":273.1,"low":262.3,"amount":18953471.5965,"amplitude":0.039863,"askPrice":270.58,"askSize":200,"bidPrice":262,"bidSize":160,"shortable":3,"etf":1,"ttmEps":8.545272,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1791379800000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":264.97,"sharesOutstanding":11450002,"nav":270.76,"aum":2951284541.52,"bidAskSpread":0.001073,"preHourTrading":{"tag":"盘前","latestPrice":264.97,"preClose":264.97,"latestTime":"04:00 EDT","volume":1,"amount":264.97,"timestamp":1791360025951,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":264.97,"preClose":264.97,"latestTime":"19:30 EDT","volume":23,"amount":6096.091,"timestamp":1791329403228,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.0580946017177977,"impliedVol":0.2498,"impliedVolPercentile":0.924},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"FBT\",,,,,undefined,":{"symbol":"FBT","floatShares":10950002,"roa":"-0.16%","roe":"19.96%","lyrEps":37.754725,"volumeRatio":1.0580946017177977,"shares":10950002,"dividePrice":0,"high":273.1,"amplitude":0.039863,"preClose":270.93,"low":262.3,"week52Low":182.08,"pbRate":"1.04","psRate":"699.94","week52High":275.23,"institutionHeld":0,"latestPrice":264.97,"committee":-0.111111,"eps":8.545272,"divideRate":0,"volume":71469,"delay":0,"ttmEps":8.545272,"open":273.1,"prevYearClose":206.52,"prevWeekClose":266.44,"prevMonthClose":272.26,"prevQuarterClose":272.26,"fiveDayClose":272.58,"twentyDayClose":265.78,"sixtyDayClose":247.54},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/FBT\",params:#limit:5,,,undefined,":[{"date":"2024-12-13","symbol":"FBT","amount":1.1726,"announcedDate":"2024-12-12","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-13","defaultRemindTime":1734100200000,"name":"First Trust NYSE Arca Biotechnology Index Fund","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-31","payableDate":"2024-12-13","currency":"USD","dateTimestamp":1734066000000,"payDate":"2024-12-31"},{"market":"US","date":"2022-01-10","symbol":"FBT","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1641790800000,"reportTimeType":"","actualEps":null},{"market":"US","date":"2021-12-30","symbol":"FBT","amount":2.2136,"defaultRemindTime":1640874600000,"name":"First Trust NYSE Arca Biotechnology Index Fund","recordDate":"2022-01-10","payableDate":"2021-12-31","currency":"USD","type":"dividend","dateTimestamp":1640840400000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"FBT\",market:\"US\",,,undefined,":[{"executeDate":"2021-12-30","recordDate":"2021-12-31","paymentDate":"2022-01-10","value":2.2136,"currency":"USD"},{"executeDate":"2024-12-13","recordDate":"2024-12-13","paymentDate":"2024-12-31","value":1.1726,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"FBT\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"FBT\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668393317","title":"Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2668393317","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668393317?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:09","pubTimestamp":1789589347,"startTime":"0","endTime":"0","summary":"Veracyte director Jens Holstein disposes of USD 204,747 common sharesVeracyte director Jens Holstein sold 5,000 common shares on Sept. 14, 2026 at a weighted average price of $40.95.Holdings fell to 2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL3rcYDf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Veracyte Director Jens Holstein Disposes of USD 204,747 Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VCYT","BK4139","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607455","title":"Alkermes Appoints Anne Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607455","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607455?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556448,"startTime":"0","endTime":"0","summary":"Alkermes appoints Anne Whitaker to board of directorsAlkermes appointed Anne C. Whitaker as an independent director to its board.Whitaker is a biopharmaceutical executive with commercial, operational,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nNDL86gXCW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","BK4139","PSIL","PSCH","MEDX","ALKS","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667607123","title":"Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2667607123","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667607123?lang=en_us&edition=fundamental","pubTime":"2026-09-16 19:00","pubTimestamp":1789556400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260916:nTUA78XSXG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ALKS","PSIL","MEDX","BK4139","IBRN","FBT","PSCH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117818184","title":"Brookfield Strikes $2.9 Billion Cash Deal for Australian Plumbing Supplier Reliance Worldwide","url":"https://stock-news.laohu8.com/highlight/detail?id=1117818184","media":"Deep News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117818184?lang=en_us&edition=fundamental","pubTime":"2026-09-16 18:40","pubTimestamp":1789555227,"startTime":"0","endTime":"0","summary":"Brookfield Asset Management has sealed an all-cash acquisition agreement for Reliance Worldwide, valuing the plumbing fittings manufacturer at an enterprise worth of $2.9 billion. The...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","BRKR","BK4121","FBT","LU0757428866.USD","TINY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161539100","title":"Fourth Bid Succeeds: Brookfield Clinches $2.9 Billion Deal for Australian Pipe Maker RWC at 32% Premium","url":"https://stock-news.laohu8.com/highlight/detail?id=1161539100","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161539100?lang=en_us&edition=fundamental","pubTime":"2026-09-16 10:34","pubTimestamp":1789526059,"startTime":"0","endTime":"0","summary":"Brookfield Asset Management has reached an agreement to acquire Reliance Worldwide Corp. in an all-cash transaction that values the Australian piping products manufacturer at roughly A$4.1 billion...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","LU1815336091.USD","LU0757428866.USD","BK4121","BRKR","TINY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667162504","title":"Veracyte Adds Another Stream to Bladder Franchise, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667162504","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667162504?lang=en_us&edition=fundamental","pubTime":"2026-09-15 23:58","pubTimestamp":1789487931,"startTime":"0","endTime":"0","summary":"Veracyte  is adding an adjacent product to its bladder franchise following its acquisition of Convergent Genomics, UBS Securities said in a Monday note.\"We view this as a strategic move by VCYT to expand menu ofofferings into urine-based monitoring,\" the note said.Late Monday, the company reported the Convergent acquisition for $150 million upfront, plus up to $30 million in milestone payments tied to reimbursement.The deal adds Convergent's UroAmp urinary tumor DNA platform, the note said, adding that it has been clinically validated in non-muscle invasive bladder cancer for therapy-response monitoring and post-treatment surveillance.\"While revenue contribution is likely a few years away, the addition of UroAmp reinforces our Buy rating and our view that VCYT has multiple growth levers capable of supporting long-duration double-digit revenue growth,\" the report said.Price: 41.18, Change: -0.03, Percent Change: -0.07","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667444786","title":"Press Release: Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2667444786","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667444786?lang=en_us&edition=fundamental","pubTime":"2026-09-15 20:00","pubTimestamp":1789473600,"startTime":"0","endTime":"0","summary":"BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (\"Legend Biotech\" or the \"Company\"), a global leader in cell therapy, today announced that its Board of ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBB","GNOM","CANC","XBI","CNCR","SYNB","BK4505","LEGN","BK4022","R","MEDI","BK4585","BK4232","BK4139","LFSC","FBT","MEMS","BK4588","BK4581","TBXU","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695415","title":"Veracyte Completes Convergent Genomics Acquisition to Expand Urology","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695415","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695415?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:31","pubTimestamp":1789417898,"startTime":"0","endTime":"0","summary":"Veracyte ( ($VCYT) ) has shared an update. On Sept. 14, 2026, Veracyte completed the acquisition of Convergent Genomics Inc., a bladder cancer-focu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/veracyte-completes-convergent-genomics-acquisition-to-expand-urology?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667373695","title":"Veracyte Buys Convergent Genomics","url":"https://stock-news.laohu8.com/highlight/detail?id=2667373695","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667373695?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:22","pubTimestamp":1789417352,"startTime":"0","endTime":"0","summary":"Veracyte  said late Monday it has acquired Convergent Genomics for $150 million in upfront cash and up to additional $30 million tied to milestones over UroAmp reimbursement efforts.The company said the acquisition expands its urology diagnostics portfolio with a urinary tumor DNA testing platform.Veracyte said it contemplated Convergent's operating expenses in 2026 adjusted EBITDA outlook and is not updating its guidance.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667695356","title":"Veracyte acquires Convergent Genomics for $150M in cash upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2667695356","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667695356?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:10","pubTimestamp":1789416629,"startTime":"0","endTime":"0","summary":"Veracyte (VCYT) announced its acquisition of Convergent Genomics. The acquisition adds Convergent Genomics’ UroAmp platform, including its propriet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veracyte-acquires-convergent-genomics-for-150m-in-cash-upfront-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","FBT","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667768693","title":"Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2667768693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667768693?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VCYT","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667693761","title":"Veracyte, - Acquisition Includes $150 Mln Upfront Cash and up to $30 Mln Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2667693761","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667693761?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FBT","BK4139","VCYT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667369376","title":"Veracyte, - Expects to Commercialize Initial Uroamp Test in Late 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2667369376","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667369376?lang=en_us&edition=fundamental","pubTime":"2026-09-15 04:05","pubTimestamp":1789416300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260914:nTUA6X8BND:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VCYT","FBT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","MEDX","BK4139","ALKS","PSCH","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AZNH","CNCR","FTXH","NVIB","MEDX","FHLC","GNMX","PJP","MEDI","IDNA","LLYX","BBH","PINK","CANC","FXH","FBT","HRTS","SBIO","SYNB","GDOC","APXH","MDTX","BBP","JDOC","PSCH","BIB","SURI","HYLG","PBE","TBXU","BME","IBBQ","GNOM","JHMH","MRNY","IBBJ","XPH","PTH","CURE","WDNA","MNTL","LFSC","PSIL","IEIH","IBB","PBPH","GSKH","IBRN","RSPH","GPCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666743153","title":"Bruker Leadership Presents at Upcoming Wells Fargo Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2666743153","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666743153?lang=en_us&edition=fundamental","pubTime":"2026-09-09 01:21","pubTimestamp":1788888090,"startTime":"0","endTime":"0","summary":"Bruker leadership presents at upcoming Wells Fargo healthcare conferenceBruker leadership to present at Wells Fargo’s 21st Annual Healthcare Conference in Boston on Sept. 9, 2026 at 8:00 a.m. ET.Morga","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL9m2WsZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BRKR","LU1815336091.USD","LU0757428866.USD","TINY","FBT","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665858375","title":"Video: Novartis slides after second recent drug development setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2665858375","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665858375?lang=en_us&edition=fundamental","pubTime":"2026-09-08 21:05","pubTimestamp":1788872716,"startTime":"0","endTime":"0","summary":"The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how the markets will open, which stocks will...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/video-novartis-slides-after-second-recent-drug-development-setback-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","LFSC","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FXH","JHMH","MEDX","RSPH","MEDI","BBP","HRTS","SYNB","HYLG","TBXU","MNTL","PJP","FHLC","GSKH","BME","PBPH","IBBQ","GPCR","IDNA","SURI","MDTX","JDOC","GNMX","GDOC","PTH","GNOM","IBRN","MRNY","PSCH","AZNH","LENZ","BIB","NVIB","PSIL","CANC","FBT","LLYX","SBIO","WDNA","XPH","IBBJ","CURE","IBB","APXH","BBH","LFSC","PBE","CNCR","FTXH","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665101723","title":"Milton Essex boosts Sanford Biotech capital to drive advanced mastitis cell therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2665101723","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665101723?lang=en_us&edition=fundamental","pubTime":"2026-09-08 02:47","pubTimestamp":1788806848,"startTime":"0","endTime":"0","summary":"MILTON ESSEX S.A. ( ($PL:MTN) ) just unveiled an announcement. Milton Essex S.A., acting as sole shareholder of Sanford Biotech, has approved a PLN...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/milton-essex-boosts-sanford-biotech-capital-to-drive-advanced-mastitis-cell-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBBQ","IBB","BK4585","TBXU","LFSC","XBI","GNOM","CNCR","MTNmain","BK4588","FBT","BK4581","SYNB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","FBT","ABVC","MEDX","BK4139","ADHD","PSCH","PSIL","IBRN"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}]}}